{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:24:27Z","timestamp":1774380267368,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd012395","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000}}],"reference-count":145,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012395.pub2","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T18:28:36Z","timestamp":1587407316000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacological treatment for familial amyloid polyneuropathy"],"prefix":"10.1002","author":[{"given":"Francesca","family":"Magrinelli","sequence":"first","affiliation":[{"name":"University of Verona; Department of Neurosciences, Biomedicine and Movement Sciences; Piazzale L.A. Scuro n. 10 Verona VR Italy 37134"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Maria","family":"Fabrizi","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Neurosciences, Biomedicine and Movement Sciences; Piazzale L.A. Scuro n. 10 Verona VR Italy 37134"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Santoro","sequence":"additional","affiliation":[{"name":"University Federico II of Naples; Department of Neurosciences, Reproductive Sciences and Odontostomatology; Via Sergio Pansini n. 5 Naples Italy 80131"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiore","family":"Manganelli","sequence":"additional","affiliation":[{"name":"University Federico II of Naples; Department of Neurosciences, Reproductive Sciences and Odontostomatology; Via Sergio Pansini n. 5 Naples Italy 80131"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampietro","family":"Zanette","sequence":"additional","affiliation":[{"name":"Pederzoli Hospital; Neurology Section; Via Monte Baldo n\u00b0 24 Peschiera del Garda VR Italy 37019"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Cavallaro","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Neurosciences, Biomedicine and Movement Sciences; Piazzale L.A. Scuro n. 10 Verona VR Italy 37134"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Tamburin","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Neurosciences, Biomedicine and Movement Sciences; Piazzale L.A. Scuro n. 10 Verona VR Italy 37134"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S31.003","DOI":"10.1212\/WNL.90.15_supplement.S31.003","article-title":"Evaluation of quality of life and disability in patients with hereditary transthyretin-mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study","volume":"90","author":"Adams","year":"2018","journal-title":"Neurology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"CT.001","DOI":"10.1212\/WNL.90.15_supplement.CT.001","article-title":"Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study","volume":"90","author":"Adams","year":"2018","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0003|cit3","first-page":"165","article-title":"Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study","volume":"12","author":"Adams","year":"2017","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"1","key":"10.1002\/14651858.CD012395.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0005|cit5","first-page":"S129","article-title":"Outcomes of patients with hereditary transthyretin-mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran","volume":"175","author":"Adams","year":"2019","journal-title":"Revue Neurologique"},{"issue":"1","key":"10.1002\/14651858.CD012395.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","article-title":"Trial design and rationale for APOLLO, a phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy","volume":"17","author":"Adams","year":"2017","journal-title":"BMC Neurology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0007|cit7","first-page":"2019","article-title":"Impact of patisiran on overall health status in HATTR amyloidosis: Results from the APOLLO trial","volume":"92","author":"Ajroud-Driss","year":"2019","journal-title":"Neurology. Conference: 71st Annual Meeting of the American Academy of Neurology, AAN"},{"issue":"4","key":"10.1002\/14651858.CD012395.pub2-BIB0008|cit8","first-page":"272","article-title":"Impact of patisiran on overall health status in hATTR amyloidosis: results from the APOLLO trial","volume":"23","author":"Ajroud-Driss","year":"2018","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"Suppl 22","key":"10.1002\/14651858.CD012395.pub2-BIB0009|cit9","first-page":"S180","article-title":"Evaluating the efficacy of patisiran in patients with hATTR amyloidosis in the phase 2 OLE trial and the phase 3 trial","volume":"84","author":"Berk","year":"2018","journal-title":"Annals of Neurology. Conference: 143rd annual meeting American Neurological Association, ANA"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012395.pub2-BIB0011|cit10","first-page":"17","article-title":"Impact of prior TTR stabilizer use in patients with hereditary transthyretin-mediated amyloidosis in the APOLLO phase-3 study of patisiran","volume":"25","author":"Coelho","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012395.pub2-BIB0012|cit11","first-page":"353","article-title":"Outcomes of patients with hereditary transthyretin-mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran","volume":"25","author":"Coelho","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0010|cit12","first-page":"S261","article-title":"Transthyretin reduction with patisiran in the APOLLO phase 3 study","volume":"5","author":"Coelho","year":"2018","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"5","key":"10.1002\/14651858.CD012395.pub2-BIB0013|cit13","first-page":"466","article-title":"Impact of patisiran on autonomic neuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis patients","volume":"28","author":"Gonzalez-Duarte","year":"2018","journal-title":"Clinical Autonomic Research"},{"issue":"4","key":"10.1002\/14651858.CD012395.pub2-BIB0014|cit14","first-page":"400","article-title":"Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment: analysis from APOLLO","volume":"23","author":"Gonzalez-Duarte","year":"2018","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD012395.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.cardfail.2019.07.222","article-title":"Impact of patisiran, an RNAi therapeutic, on orthostatic intolerance in patients with hereditary transthyretin-mediated amyloidosis","volume":"25","author":"Judge","year":"2019","journal-title":"Journal of Cardiac Failure"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0016|cit16","first-page":"S220","article-title":"Impact of patisiran on autonomic neuropathy in hereditary transthyretin-mediated amyloidosis patients","volume":"5","author":"Mauermann","year":"2018","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0017|cit17","first-page":"383","article-title":"Impact of patisiran on Norfolk QOL-DN in patients with hereditary transthyretin-mediated amyloidosis: results from the cardiac subpopulation in the phase 3 APOLLO study","volume":"20","author":"Merlini","year":"2018","journal-title":"European Journal of Heart Failure"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012395.pub2-BIB0018|cit18","first-page":"459","article-title":"Impact of patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL-DN) in patients with hereditary transthyretin-mediated amyloidosis: results from the phase-3 APOLLO study","volume":"25","author":"Obici","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012395.pub2-BIB0019|cit19","first-page":"17","article-title":"Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin-mediated amyloidosis","volume":"25","author":"Obici","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0020|cit20","first-page":"165","article-title":"Reasons for discontinuation of TTR stabilizers and\/or TTR fibril disrupter: an analysis of baseline demographics of patients with hereditary ATTR (hATTR) amyloidosis in the phase 3 APOLLO study","volume":"12","author":"Partisano","year":"2017","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"4","key":"10.1002\/14651858.CD012395.pub2-BIB0021|cit21","first-page":"352","article-title":"Infusion related reactions in patients with hATTR amyloidosis treated with patisiran","volume":"23","author":"Polydefkis","year":"2018","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012395.pub2-BIB0022|cit22","first-page":"S51","article-title":"Evaluating the impact of patisiran on disability using the Rasch-built overall disability scale (R-ODS) in patients with hereditary transthyretin-mediated (HATTR) amyloidosis in the APOLLO study","volume":"58","author":"Quan","year":"2018","journal-title":"Muscle & Nerve"},{"issue":"Suppl 21","key":"10.1002\/14651858.CD012395.pub2-BIB0023|cit23","first-page":"S100","article-title":"Reasons for discontinuation of TTR stabilizers and\/or TTR fibril disrupter: an analysis of baseline demographics of patients with hATTR amyloidosis in the phase 3 APOLLO study","volume":"82","author":"Schmidt","year":"2017","journal-title":"Annals of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0024|cit24","first-page":"576","article-title":"Analysis of NT-proBNP baseline levels in APOLLO as a predictor of survival in hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"20","author":"Slama","year":"2018","journal-title":"European Journal of Heart Failure"},{"issue":"4","key":"10.1002\/14651858.CD012395.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Analysis of the APOLLO study","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0026|cit26","first-page":"19","article-title":"Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"19","author":"Zhang","year":"2019","journal-title":"Journal of Clinical Pharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0027|cit27","first-page":"S31","article-title":"Results from APOLLO phase III study of patisiran, the first approved RNAi therapeutic, in hereditary ATTR amyloidosis patients with polyneuropathy","volume":"105","author":"Zhang","year":"2019","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD012395.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.hrtlng.2019.08.004","article-title":"Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO-TTR","volume":"48","author":"Anonymous","year":"2019","journal-title":"Heart & Lung"},{"issue":"14 Suppl","key":"10.1002\/14651858.CD012395.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"S50.006","DOI":"10.1212\/WNL.84.14_supplement.S50.006","article-title":"A phase 3 study to evaluate ISIS-TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics","volume":"84","author":"Benson","year":"2015","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0030|cit30","first-page":"165","article-title":"Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)","volume":"12","author":"Benson","year":"2017","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"1","key":"10.1002\/14651858.CD012395.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012395.pub2-BIB0032|cit32","first-page":"376","article-title":"Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO-TTR","volume":"25","author":"Coelho","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012395.pub2-BIB0033|cit33","first-page":"375","article-title":"Baseline characteristics of patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy enrolled in the phase 3 study NEURO-TTR demonstrate significant disease burden","volume":"25","author":"Conceicao","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD012395.pub2-BIB0034|cit34","first-page":"P3.9","article-title":"Responsiveness of neuropathy symptom and change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy","volume":"92","author":"Dyck","year":"2019","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0035|cit35","first-page":"715","article-title":"Responsiveness of Neuropathy Symptom and Change (NSC) score components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy","volume":"26","author":"Dyck","year":"2019","journal-title":"European Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0036|cit36","first-page":"714","article-title":"Responsiveness of mNIS+7 components in inotersen treatment of hereditary transthyretin amyloidosis polyneuropathy","volume":"26","author":"Dyck","year":"2019","journal-title":"European Journal of Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012395.pub2-BIB0037|cit37","first-page":"S55","article-title":"Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO-TTR)","volume":"58","author":"Gertz","year":"2018","journal-title":"Muscle & Nerve"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0038|cit38","article-title":"Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO-TTR)","volume":"90","author":"Gertz","year":"2018","journal-title":"Neurology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"N2.001","DOI":"10.1212\/WNL.90.15_supplement.N2.001","article-title":"Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO-TTR)","volume":"90","author":"Gertz","year":"2018","journal-title":"Neurology"},{"issue":"11 Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0040|cit40","first-page":"1217M","article-title":"Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO-TTR","volume":"71","author":"Maurer","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012395.pub2-BIB0041|cit41","first-page":"S54","article-title":"Inotersen improves Norfolk quality of life-diabetic neuropathy (Norfolk QOL-DN) measures in patients with hereditary transthyretin (HATTR) amyloidosis in the phase 3 study NEURO-TTR","volume":"58","author":"Polydefkis","year":"2018","journal-title":"Muscle & Nerve"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012395.pub2-BIB0042|cit42","first-page":"568","article-title":"Inotersen improved Norfolk quality of life-diabetic neuropathy (Norfolk QOL-DN) measures in patients with hereditary transthyretin (hATTR) amyloidosis treated in the phase-3 study NEURO-TTR","volume":"25","author":"Vita","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012395.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/13506129.2018.1503593","article-title":"Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial","volume":"25","author":"Waddington-Cruz","year":"2018","journal-title":"Amyloid"},{"issue":"Suppl 21","key":"10.1002\/14651858.CD012395.pub2-BIB0044|cit44","first-page":"S109","article-title":"Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (neuro-TTR)","volume":"82","author":"Wang","year":"2017","journal-title":"Annals of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1182\/blood-2018-99-119578","article-title":"Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR Amyloidosis: results from a double-blind placebo-controlled trial","volume":"132","author":"Yarlas","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1182\/blood-2018-99-119578","article-title":"Impact of inotersen on functioning and activities of daily living for patients with hereditary TTR amyloidosis: results from a double-blind placebo-controlled trial","volume":"132","author":"Yarlas","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1182\/blood-2018-99-119216","article-title":"Impact of inotersen on subgroups of patients with hereditary TTR amyloidosis: results from a double-blind placebo-controlled trial","volume":"132","author":"Yarlas","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0048|cit48","first-page":"78","article-title":"The diflunisal trial: update on study drug tolerance and disease progression","volume":"17","author":"Berk","year":"2010","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/13506129.2011.574354073","article-title":"The diflunisal trial: update on study drug tolerance and disease progression","volume":"18","author":"Berk","year":"2011","journal-title":"Amyloid"},{"issue":"24","key":"10.1002\/14651858.CD012395.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"2658-67","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/13506129.2012.678509","article-title":"The Diflunisal Trial: study accrual and drug tolerance","volume":"19","author":"Berk","year":"2012","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0056|cit52","first-page":"8","article-title":"Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies","volume":"19","author":"Coelho","year":"2012","journal-title":"European Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0052|cit53","first-page":"75","article-title":"Tafamidis (Fx-1006A): A first-in-class disease-modifying therapy for transthyretin familial amyloid","volume":"17","author":"Coelho","year":"2010","journal-title":"Amyloid"},{"issue":"6","key":"10.1002\/14651858.CD012395.pub2-BIB0053|cit54","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1016\/j.clinph.2011.11.219","article-title":"Tafamidis and nerve fiber function in transthyretin-type familial amyloid polyneuropathy","volume":"123","author":"Coelho","year":"2012","journal-title":"Clinical Neurophysiology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012395.pub2-BIB0054|cit55","first-page":"35","article-title":"A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx-1006A, in patients with TTR amyloid polyneuropathy: a phase II\/III randomized, double-blind, placebo-controlled study","volume":"14","author":"Coelho","year":"2009","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"8","key":"10.1002\/14651858.CD012395.pub2-BIB0055|cit56","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD012395.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2017.1301419","article-title":"Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial","volume":"24","author":"Keohane","year":"2017","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0058|cit58","first-page":"413","article-title":"Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: Supportive post-hoc analyses of a pivotal trial","volume":"22","author":"Keohane","year":"2015","journal-title":"European Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"P11","DOI":"10.1186\/1750-1172-10-S1-P11","article-title":"Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post-hoc analyses of a pivotal trial","volume":"10","author":"Keohane","year":"2015","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0060|cit60","first-page":"775","article-title":"Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy","volume":"19","author":"Suhr","year":"2012","journal-title":"European Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD012395.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40120-014-0023-8","article-title":"Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis","volume":"3","author":"Suhr","year":"2014","journal-title":"Neurology and Therapy"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD012395.pub2-BIB0062|cit62","first-page":"19","article-title":"Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24-month safety and efficacy in subgroup of patients with cardiac involvement","volume":"19","author":"Adams","year":"2017","journal-title":"European Journal of Heart Failure"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0063|cit63","first-page":"31","article-title":"Phase 2 open-label extension (OLE) study of patisiran with or without a TTR stabilizer for the treatment of hereditary ATTR (hATTR) amyloidosis with polyneuropathy","volume":"24","author":"Adams","year":"2017","journal-title":"European Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD012395.pub2-BIB0064|cit64","first-page":"A211","article-title":"Phase 2 open-label extension (OLE) study of patisiran, an investigational RNA interference (RNAi) therapeutic for the treatment of hereditary attr amyloidosis with polyneuropathy","volume":"20","author":"Adams","year":"2017","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-10-S1-O20","article-title":"Phase 2 open-label extension (OLE) study of patisiran, an investigational siRNA agent for familial amyloidotic polyneuropathy (FAP)","volume":"10","author":"Adams","year":"2015","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012395.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","article-title":"Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years","volume":"24","author":"Barroso","year":"2017","journal-title":"Amyloid"},{"issue":"11","key":"10.1002\/14651858.CD012395.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-10-S1-O21","article-title":"Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis","volume":"10","author":"Gillmore","year":"2015","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012395.pub2-BIB0069|cit69","first-page":"294","article-title":"Tafamidis delays disease progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy","volume":"22","author":"Gundapaneni","year":"2017","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0070|cit70","first-page":"165","article-title":"Tafamidis delays disease progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy","volume":"12","author":"Gundapaneni","year":"2017","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012395.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/ene.13510","article-title":"Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy","volume":"25","author":"Gundapaneni","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD012395.pub2-BIB0072|cit72","first-page":"e003815","article-title":"Design and rationale of the phase 3 ATTR-ACT clinical trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)","volume":"10","author":"Maurer","year":"2017","journal-title":"Circulation: Heart Failure"},{"issue":"11","key":"10.1002\/14651858.CD012395.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"9 Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0735-1097(19)31516-5","article-title":"Safety of inotersen treatment in patients with transthyretin amyloid cardiomyopathy","volume":"73","author":"Dasgupta","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012395.pub2-BIB0075|cit75","first-page":"30","article-title":"Long-term efficacy and safety of Inotersen in patients with hereditary transthyretin (hATTR) amyloidosis treated in the open-label extension of the phase-3 study NEURO-TTR","volume":"25","author":"Plante-Bordeneuve","year":"2018","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0076|cit76","first-page":"S99","article-title":"Neurological data collection protocol on tafamidis meglumine treatment for familial amyloid polyneuropathy: Preliminary data on patients enrolled by the Italian network","volume":"18","author":"Russo","year":"2013","journal-title":"Journal of the Peripheral Nervous System"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0077|cit77","first-page":"S48","article-title":"Safety and tolerability of orally administered tafamidis meglumine in TTR FAP: Preliminary data at 3-month follow-up","volume":"17","author":"Russo","year":"2012","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"5","key":"10.1002\/14651858.CD012395.pub2-BIB0078|cit78","first-page":"A55","article-title":"ALN-TTR, an RNAI therapeutic for the treatment of transthyretin amyloidosis","volume":"21","author":"Sah","year":"2011","journal-title":"Nucleic Acid Therapeutics"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0080|cit80","first-page":"P6","article-title":"Early intervention with tafamidis provides long-term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy","volume":"10","author":"Waddington-Cruz","year":"2015","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012395.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/13506129.2016.1207163","article-title":"Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy","volume":"23","author":"Waddington-Cruz","year":"2016","journal-title":"Amyloid"},{"issue":"2","key":"10.1002\/14651858.CD012395.pub2-BIB0082|cit82","first-page":"244","article-title":"Early intervention with tafamidis provides long-term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy","volume":"20","author":"Waddington-Cruz","year":"2015","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"5","key":"10.1002\/14651858.CD012395.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1046\/j.1464-5491.2002.00698.x","article-title":"The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort","volume":"19","author":"Abbott","year":"2002","journal-title":"Diabetic Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012395.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1756285612470192","article-title":"Recent advances in the treatment of familial amyloid polyneuropathy","volume":"6","author":"Adams","year":"2013","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"3","key":"10.1002\/14651858.CD012395.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11910-013-0435-3","article-title":"FAP neuropathy and emerging treatments","volume":"14","author":"Adams","year":"2014","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"3","key":"10.1002\/14651858.CD012395.pub2-BIB0086|cit86","first-page":"408-27","article-title":"A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves","volume":"75","author":"Andrade","year":"1952","journal-title":"Brain"},{"issue":"1","key":"10.1002\/14651858.CD012395.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0272-7358(88)90050-5","article-title":"Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation","volume":"8","author":"Beck","year":"1988","journal-title":"Clinical Psychology Review"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000052074","article-title":"NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy","volume":"41","author":"Bril","year":"1999","journal-title":"European Neurology"},{"issue":"2","key":"10.1002\/14651858.CD012395.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fj.05-4509com","article-title":"Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model","volume":"20","author":"Cardoso","year":"2006","journal-title":"FASEB Journal"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined Doxycycline\/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"Journal of Translational Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012395.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.clinph.2016.02.013","article-title":"The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy","volume":"127","author":"Castro","year":"2016","journal-title":"Clinical Neurophysiology"},{"issue":"3","key":"10.1002\/14651858.CD012395.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1586\/14737175.2015.1013097","article-title":"Progress in the treatment of small fiber peripheral neuropathy","volume":"15","author":"Chiang","year":"2015","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"3","key":"10.1002\/14651858.CD012395.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/mus.25257","article-title":"Clinical measures in transthyretin familial amyloid polyneuropathy","volume":"55","author":"Coelho","year":"2017","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0094|cit94","first-page":"88","article-title":"Forty years of experience with type I amyloid neuropathy. Review of 483 cases","volume-title":"Amyloid and Amyloidosis","author":"Coutinho","year":"1980"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0095|cit95","unstructured":"Veritas Health Innovation Covidence"},{"issue":"12","key":"10.1002\/14651858.CD012395.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1684-8","DOI":"10.1007\/s00415-007-0617-5","article-title":"A brief compound test for assessment of autonomic and sensory-motor dysfunction in familial amyloid polyneuropathy","volume":"254","author":"Denier","year":"2007","journal-title":"Journal of Neurology"},{"issue":"1078","key":"10.1002\/14651858.CD012395.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/postgradmedj-2014-133224","article-title":"The transthyretin amyloidoses: advances in therapy","volume":"91","author":"Dubrey","year":"2015","journal-title":"Postgraduate Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD012395.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1212\/WNL.45.6.1115","article-title":"Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects","volume":"45","author":"Dyck","year":"1995","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD012395.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1212\/WNL.49.1.229","article-title":"Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort","volume":"49","author":"Dyck","year":"1997","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD012395.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/mus.25563","article-title":"Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial","volume":"56","author":"Dyck","year":"2017","journal-title":"Muscle & Nerve"},{"issue":"1","key":"10.1002\/14651858.CD012395.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"e29933","DOI":"10.1371\/journal.pone.0029933","article-title":"Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: \"in vivo\" evidence from FAP mice models","volume":"7","author":"Ferreira","year":"2012","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0103|cit103","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/TACG.S19903","article-title":"Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis","volume":"5","author":"Hund","year":"2012","journal-title":"The Application of Clinical Genetics"},{"issue":"7","key":"10.1002\/14651858.CD012395.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/dmrr.1223","article-title":"Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes","volume":"27","author":"Kempler","year":"2011","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"issue":"Pt 3","key":"10.1002\/14651858.CD012395.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/brain\/awu344","article-title":"In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography","volume":"138","author":"Kollmer","year":"2015","journal-title":"Brain"},{"issue":"5","key":"10.1002\/14651858.CD012395.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1212\/WNL.0000000000004178","article-title":"Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools","volume":"89","author":"Kollmer","year":"2017","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD012395.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","article-title":"Green tea halts progression of cardiac transthyretin amyloidosis: an observational report","volume":"101","author":"Kristen","year":"2012","journal-title":"Clinical Research in Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD012395.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1635-7","DOI":"10.1212\/WNL.39.12.1635","article-title":"A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis","volume":"39","author":"Lacomblez","year":"1989","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD012395.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ene.12225","article-title":"Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy","volume":"20","author":"Lozeron","year":"2013","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/9781118486160.ch10","article-title":"Nerve and muscle disease","volume-title":"Neurology: a Queen Square Textbook","author":"Lunn","year":"2016"},{"issue":"6","key":"10.1002\/14651858.CD012395.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.24519","article-title":"Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France","volume":"78","author":"Mariani","year":"2015","journal-title":"Annals of Neurology"},{"issue":"23","key":"10.1002\/14651858.CD012395.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1212\/WNL.0000000000004016","article-title":"Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy","volume":"88","author":"Masuda","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD012395.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/187152907780059029","article-title":"Orthostatic hypotension: evaluation and treatment","volume":"7","author":"Maule","year":"2007","journal-title":"Cardiovascular & Hematological Disorders Drug Targets"},{"issue":"6","key":"10.1002\/14651858.CD012395.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","article-title":"Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis","volume":"6","author":"Merlini","year":"2013","journal-title":"Journal of Cardiovascular Translational Research"},{"issue":"7","key":"10.1002\/14651858.CD012395.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012395.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1529-8027.2011.00350.x","article-title":"Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease","volume":"16","author":"Murphy","year":"2011","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"2","key":"10.1002\/14651858.CD012395.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1681\/ASN.2016090951","article-title":"Hereditary lysozyme amyloidosis variant p.Leu102Ser associates with unique phenotype","volume":"28","author":"Nasr","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"},{"issue":"12","key":"10.1002\/14651858.CD012395.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","article-title":"Familial amyloid polyneuropathy","volume":"10","author":"Plant\u00e9-Bordeneuve","year":"2011","journal-title":"Lancet Neurology"},{"issue":"4","key":"10.1002\/14651858.CD012395.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s00415-017-8708-4","article-title":"Transthyretin familial amyloid polyneuropathy: an update","volume":"265","author":"Plant\u00e9-Bordeneuve","year":"2018","journal-title":"Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012395.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"478-82","DOI":"10.1002\/ana.410380323","article-title":"Diabetic polyneuropathy in controlled clinical trials: consensus report of the Peripheral Nerve Society","volume":"38","author":"Peripheral Nerve Society","year":"1995","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD012395.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQolGroup","volume":"33","author":"Rabin","year":"2001","journal-title":"Annals of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012395.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nature Reviews. Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD012395.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"European Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012395.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"P9","DOI":"10.1186\/1750-1172-10-S1-P9","article-title":"SOM0226, a repositioned compound for the treatment of TTR amyloidosis","volume":"10","author":"Reig","year":"2015","journal-title":"Orphanet Journal of Rare Disease"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0127|cit127","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"9","key":"10.1002\/14651858.CD012395.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"E2403","DOI":"10.1002\/humu.22619","article-title":"Online registry for mutations in hereditary amyloidosis including nomenclature recommendations","volume":"35","author":"Rowczenio","year":"2014","journal-title":"Human Mutation"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0129|cit129","unstructured":"Rowczenio D Wechalekar A Mutations in transthyretin gene amyloidosismutations.com\/mut-attr.php 2015"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0130|cit130","first-page":"361","article-title":"Plasma exchanges on: the treatment of familial amyloidotic polyneuropathy, Portuguese type. Familial amyloidotic polyneuropathy and other transthyretin related disorders","volume":"3","author":"Sales-Lu\u00eds","year":"1990","journal-title":"Arquivos de Medicina"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"10787","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"7","author":"Sant'Anna","year":"2016","journal-title":"Nature Communications"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0132|cit132","unstructured":"User's manual for the SF-36v2 survey 3rd ed. Lincoln (RD), Quality Metric Incorporated 2011"},{"issue":"7","key":"10.1002\/14651858.CD012395.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1212\/01.WNL.0000156517.00615.A3","article-title":"Reliability and validity of the CMT neuropathy score as a measure of disability","volume":"64","author":"Shy","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD012395.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/13506129.2014.964858","article-title":"Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis","volume":"21","author":"Sipe","year":"2014","journal-title":"Amyloid"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"387-97","DOI":"10.1111\/j.0954-6820.1983.tb08613.x","article-title":"Familial amyloidosis with polyneuropathy. A long-term follow-up of 21 patients with special reference to gastrointestinal symptoms","volume":"214","author":"Steen","year":"1983","journal-title":"Acta Medica Scandinavica"},{"issue":"1-2","key":"10.1002\/14651858.CD012395.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jns.2014.06.041","article-title":"Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials","volume":"344","author":"Suanprasert","year":"2014","journal-title":"Journal of the Neurological Sciences"},{"issue":"5","key":"10.1002\/14651858.CD012395.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2796.1994.tb01106.x","article-title":"Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy","volume":"235","author":"Suhr","year":"1994","journal-title":"Journal of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012395.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(99)00231-2","article-title":"Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients","volume":"171","author":"Tashima","year":"1999","journal-title":"Journal of the Neurological Sciences"},{"issue":"24","key":"10.1002\/14651858.CD012395.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1056\/NEJMoa1201356","article-title":"Hereditary Systemic Amyloidosis Due to Asp76Asn Variant \u03b22-Microglobulin","volume":"366","author":"Valleix","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012395.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"Nes","year":"2011","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012395.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/dia.2005.7.497","article-title":"The development and validation of the Norfolk QOL-DN, a new measure of patients\u2019 perception of the effects of diabetes and diabetic neuropathy","volume":"7","author":"Vinik","year":"2005","journal-title":"Diabetes Technology & Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD012395.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"473-83","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Medical Care"},{"issue":"11","key":"10.1002\/14651858.CD012395.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"2597-604","DOI":"10.1111\/j.1600-6143.2007.01969.x","article-title":"Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years","volume":"7","author":"Yamamoto","year":"2007","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD012395.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"2220-4","DOI":"10.1002\/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q","article-title":"Evaluation of patients with advanced cancer using the Karnofsky performance status","volume":"45","author":"Yates","year":"1980","journal-title":"Cancer"},{"issue":"10","key":"10.1002\/14651858.CD012395.pub2-BIB0145|cit145","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012395","article-title":"Pharmacological treatment for familial amyloid neuropathy","author":"Magrinelli","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T09:27:57Z","timestamp":1722763677000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD012395.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":145,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012395.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,20]]}}}